JP2019513726A5 - - Google Patents

Info

Publication number

JP2019513726A5

JP2019513726A5 JP2018552076A JP2018552076A JP2019513726A5 JP 2019513726 A5 JP2019513726 A5 JP 2019513726A5 JP 2018552076 A JP2018552076 A JP 2018552076A JP 2018552076 A JP2018552076 A JP 2018552076A JP 2019513726 A5 JP2019513726 A5 JP 2019513726A5

Authority

JP

Japan

Prior art keywords

antibody

amino acid

acid sequence

cdr

sequence seq

Prior art date

2017-04-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 104
• 230000005764 inhibitory process Effects 0.000 claims description 31
• 230000001404 mediated effect Effects 0.000 claims description 26
• 102100022133 Complement C3 Human genes 0.000 claims description 24
• 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 22
• 239000008194 pharmaceutical composition Substances 0.000 claims description 19
• 238000003776 cleavage reaction Methods 0.000 claims description 12
• 230000007017 scission Effects 0.000 claims description 12
• 230000000295 complement effect Effects 0.000 claims description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
• 108090000056 Complement factor B Proteins 0.000 claims description 7
• 102000003712 Complement factor B Human genes 0.000 claims description 7
• 230000008021 deposition Effects 0.000 claims description 6
• 210000001124 body fluid Anatomy 0.000 claims description 5
• 239000010839 body fluid Substances 0.000 claims description 5
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• 206010018910 Haemolysis Diseases 0.000 claims description 4
• 210000004027 cell Anatomy 0.000 claims description 4
• 201000010099 disease Diseases 0.000 claims description 4
• 208000035475 disorder Diseases 0.000 claims description 4
• 230000000694 effects Effects 0.000 claims description 4
• 239000012634 fragment Substances 0.000 claims description 4
• 230000008588 hemolysis Effects 0.000 claims description 4
• 229920001184 polypeptide Polymers 0.000 claims description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 3
• 230000015572 biosynthetic process Effects 0.000 claims description 3
• 210000003743 erythrocyte Anatomy 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 230000037361 pathway Effects 0.000 claims description 3
• 108010028780 Complement C3 Proteins 0.000 claims description 2
• 102000016550 Complement Factor H Human genes 0.000 claims description 2
• 108010053085 Complement Factor H Proteins 0.000 claims description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
• 206010039509 Scab Diseases 0.000 claims description 2
• 230000006037 cell lysis Effects 0.000 claims description 2
• 239000000178 monomer Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 102000004169 proteins and genes Human genes 0.000 claims description 2
• 108090000623 proteins and genes Proteins 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 15
• 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 2
• 206010064930 age-related macular degeneration Diseases 0.000 claims 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 208000002780 macular degeneration Diseases 0.000 claims 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
• 230000021917 activation of membrane attack complex Effects 0.000 claims 1
• 239000012530 fluid Substances 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 238000000034 method Methods 0.000 description 28
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 20
• 238000007918 intramuscular administration Methods 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 206010057248 Cell death Diseases 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1